Skip to navigation Skip to content

Gilenya®: What Is It And How Does It Work (video)


Part one of a two-part interview with Aaron Miller, MD, who discusses Gilenya®, a new oral therapy for multiple sclerosis. Dr. Miller explains how the medication works, clinical trials findings, and potential side effects.

In 2018 the U.S. Food and Drug Administration approved the expansion of the use of the oral MS therapy Gilenya® (fingolimod, Novartis AG) to include the treatment of children and adolescents 10 years of age or older with relapsing MS.

To learn more about Gilenya® and other disease modifying treatment options, download the Consensus on Disease-Modifying Therapies, summary and medication guide.


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.